References
- Almyroudi M, Dimopoulos G, Halvatsiotis P. The role of diabetes mellitus and obesity in COVID 19 patients. Pneumonia. 2020;33(3):114-116.
- Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859–65.
- Bilaloglu S, Aphinyanaphongs Y, Jones S, et al. Thrombosis in Hospitalized Patients with COVID-19 in a New York City Health System. JAMA. 2020.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
- Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2020;50(1):72–81.
- Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med [Internet]. 2020 February 28;382(18):1708–20. Available from: https://doi.org/10.1056/NEJMoa2002032
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
- Spanakis M, Zoumpoulakis M, Patelarou A, et al. COVID-19 epidemic: Comparison of three European countries with different outcome using Gompertz function method. Pneumonia. 2020;33(2):1-6.
- Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. Vol. 20, Current Opinion in Hematology. 2013. p. 437–44.
- Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458–64.
- Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844– 7.
- Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738–42.
- Ikesaka R, Delluc A, Le Gal G, et al. Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: A systematic review and meta-analysis. Thromb Res. 2014;133(4):682–7.
- Marietta M, Ageno W, Artoni A, et al. COVID-19 and haemostasis: A position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus. 2020;18(3):167–9.
- Riker RR, May TL, Fraser GL, et al. Heparin‐induced thrombocytopenia with thrombosis in COVID‐19 adult respiratory distress syndrome. Res Pract Thromb Haemost. 2020;4(5):936–41.
- Schindewolf M, Steindl J, Beyer-Westendorf J, et al. Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia. J Am Coll Cardiol. 2017;70(21):2636–48.
- Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020.
- McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. Circulation Research. 2020. p. 571–87.
- Manne BK, Denorme F, Middleton EA, et al. Platelet Gene Expression and Function in COVID-19 Patients. Blood. 2020.